Skip to Content

Notice

Able Laboratories, Inc.; Withdrawal of Approval of Ten Abbreviated New Drug Applications

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of ten abbreviated new drug applications (ANDAs) held by Able Laboratories, Inc. (Able Labs), One Able Dr., Cranbury, NJ 08512. Able Labs has initiated a class II recall of the products covered by these ANDAs. The company has requested that the applications be withdrawn and has waived its opportunity for a hearing.

DATES:

Effective August 29, 2005.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

On May 25, 2005, Able Labs notified the agency that, because of improper laboratory practices and noncompliance with standard operating procedures, Able Labs was initiating a voluntary, class II recall of the products covered by the ANDAs listed in the table of this document. The company voluntarily requested withdrawal of approval of the ANDAs under § 314.150(d) (21 CFR 314.150(d)), and waived its opportunity for a hearing, provided under § 314.150(a) and (b). The following ANDAs are affected by this action:

ANDA No.Drug
40-395Diphenoxylate Hydrochloride (HCl) and Atropine Sulfate Tablets USP, 2.5 milligrams (mg)/0.025 mg
40-404Methylphenidate HCl Tablets USP, 5 mg, 10 mg, and 20 mg
40-407Prochlorperazine Suppositories USP, 2.5 mg, 5 mg, and 25 mg
40-452Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/30 mg
40-459Acetaminophen and Codeine Phosphate Tablets USP, 300 mg/60 mg
71-780Clorazepate Dipotassium Tablets USP, 3.75 mg
71-781Clorazepate Dipotassium Tablets USP, 7.5 mg
71-782Clorazepate Dipotassium Tablets USP, 15 mg
Start Printed Page 51076
75-838Propoxyphene Napsylate and Acetaminophen Tablets USP, 100 mg/650 mg
76-032Methylphenidate HCl Exended-Release Tablets USP, 20 mg

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.105(a)), approval of the ANDAs listed in the table of this document, and all amendments and supplements thereto, is withdrawn, effective August 29, 2005. Thereafter, distribution of the products in interstate commerce without approved applications is illegal and subject to regulatory action. Also, on the basis of the circumstances described in this document that led to the recall of the products and their subsequent removal from the market, the agency will remove the products from the agency's list of drug products with effective approvals, published under the title “Approved Drug Products With Therapeutic Equivalence Evaluations.” This document serves as notice of the removal of the products covered by the ANDAs listed in this document from the list of approved drug products. Distribution of these products in interstate commerce without approved applications is illegal and subject to regulatory action (see sections 505(a) and 301(d) of the act (21 U.S.C. 355(a) and 331(d)).

Start Signature

Dated: August 15, 2005.

Steven Galson,

Director, Center for Drug Evaluation and Research.

End Signature End Supplemental Information

[FR Doc. 05-17151 Filed 8-26-05; 8:45 am]

BILLING CODE 4160-01-S